Intensity Therapeutics Reports Third Quarter 2024 Financial …
2 days ago · Third Quarter 2024 Financial Results Research and development expenses were $2.2 million for the three months ended September 30, 2024, compared to $1.4 million for the …
OFF
Intensity Therapeutics Reports Third Quarter 2024 Financial …
1 week from now
2 days ago · Third Quarter 2024 Financial Results Research and development expenses were $2.2 million for the three months ended September 30, 2024, compared to $1.4 million for the …
intensitytherapeutics.com
OFF
Intensity Therapeutics Reports Third Quarter Financial Results And ...
1 week from now
Nov 13, 2023 · Third Quarter 2023 Financial Highlights Research and Development (R&D) Expenses were $1.4 million for the three months ended September 30, 2023, as compared to …
intensitytherapeutics.com
OFF
TScan Therapeutics Reports Third Quarter 2024 Financial Results …
1 week from now
4 days ago · Revenue: Revenue for the third quarter of 2024 was $1.0 million, compared to $3.9 million for the third quarter of 2023. The decrease was primarily due to timing of research …
tscan.com
OFF
Rani Therapeutics Reports Third Quarter 2024 Financial Results ...
1 week from now
1 day ago · Third Quarter 2024 Financial Results: Cash, cash equivalents and marketable securities as of September 30, 2024 totaled $30.4 million, compared to $48.5 million for the …
businessinsider.com
OFF
INTS - Intensity Therapeutics, Inc. | News | OTC Markets
1 week from now
3 days ago · Research and development expenses were $2.2 million for the three months ended September 30, 2024, compared to $1.4 million for the same period in 2023. The increase was …
otcmarkets.com
OFF
Intensity Therapeutics Reports Third Quarter Financial Results And ...
1 week from now
Nov 13, 2023 · Intensity received a total of $20.2 million in net proceeds from the transaction, providing sufficient cash and cash equivalents to fund operations into the second half of 2025. …
yahoo.com
OFF
Kyverna Therapeutics Provides Business Update And Reports Third …
1 week from now
2 days ago · For the quarter ended September 30, 2024, the company reported a net loss of $34.3 million, or a net loss per common share of $0.80, compared to a net loss of $15.5 …
prnewswire.com
OFF
Intensity Therapeutics Reports First Quarter 2024 Financial Results …
1 week from now
May 9, 2024 · Cash and investments of $10.5 million expected to fund operations through the end of the first quarter of 2025; SHELTON, Conn., May 9, 2024 /PRNewswire/ -- Intensity …
intensitytherapeutics.com
OFF
Chemomab Therapeutics Announces Third Quarter 2024 Financial …
1 week from now
2 days ago · Cash Position and Liquidity: Cash and short-term bank deposits were $19.5 million as of September 30, 2024, as compared to $12.8 million as of June 30, 2024 and $19.9 million …
financialcontent.com
OFF
Chemomab Therapeutics Announces Third Quarter 2024 Financial …
1 week from now
1 day ago · Cash Position and Liquidity: Cash and short-term bank deposits were $19.5 million as of September 30, 2024, as compared to $12.8 million as of June 30, 2024 and $19.9 million as …
biospace.com
OFF
TScan Therapeutics Reports Third Quarter 2024 Financial
1 week from now
4 days ago · Revenue: Revenue for the third quarter of 2024 was $1.0 million, compared to $3.9 million for the third quarter of 2023. The decrease was primarily due to timing of research …
globenewswire.com
Install CouponFollow Extension on Chrome
Install the CouponFollow extension to search for discount codes when shopping the fastest!
Install CouponFollow Chrome Extension
Listing Store by Characters
